FiteBac is beginning the next phase of development – Pharma
Imagine a world where the materials we interact with daily, from medical devices to dental restoratives, are not just inert surfaces but active agents in promoting health, a world where surfaces have the power to continuously fight against bacteria, fungi, and viruses, ensuring a safer, healthier environment for all.
FiteBac is at the forefront of antimicrobial technology, a firm grounded in scientific rigor, backed by international scientists, and evidenced through numerous scientific publications and clinical trials.
Here’s why FiteBac stands out in the biotech landscape:
FiteBac holds a robust portfolio of composition of matter patents in key markets including the U.S., Europe, and China, protecting its groundbreaking silsesquioxanes, elastomers, and drug technologies.
FDA Recognitions and Clearances:
FiteBac has secured FDA recognition for its new molecular entity, the K21 QAS drug, a topical antimicrobial solution, and has FDA clearances for its medical devices, demonstrating our commitment to meeting the highest standards of safety and efficacy.
Global Presence and Collaborative Endeavors:
FiteBac is not just a company but a globally recognized entity, having presented its innovative solutions at the world’s largest dental conference, IDS 2021 in Germany.
Moreover, FiteBac has forged strategic partnerships with industry leaders like RDAbbott and Siltech to develop materials with broad antimicrobial properties.
A Vision for a Healthier World:
At its core, FiteBac is driven by a mission to make the world a healthier place, leveraging its antimicrobial technology to foster well-being across communities globally.
As we stand on the cusp of a revolution in antimicrobial technology, FiteBac Pharma invites you to be a part of this journey, a journey towards a safer, healthier future, a journey paved with innovation, collaboration, and a steadfast commitment to improving lives.
Join us, as we shape a healthier tomorrow, today.
Composition of matter patents maintained in U.S., Europe, China
U.S. patents granted – silsesquioxanes, elastomers, drug
Trademarks received U.S., Europe, China, India, and Brazil
K21 QAS DRUG
FDA Drug Master file K21 QAS DRUG
FDA NDA 128706 K21 QAS DRUG Topical Antimicrobial
FDA cleared medical devices
FDA Device Master file with K21 QAS
FDA Device Master file with K18 QAMS
U.S.-Based FiteBac Presents in Germany for First Time at International Dental Show, IDS2021, to Feature New Antimicrobial Additives for Dental Restorative MaterialsSummary: FiteBac will be a new, featured presenter at the world’s largest dental conference, IDS 2021,...
FiteBac Technology and Siltech team up to manufacture novel antimicrobial silsesquioxanes with advanced properties.
Summary: After the successful launch of multiple FDA-cleared antimicrobial dental devices, FiteBac partners with Siltech, an international corporation specializing in innovative silicone products, to develop novel materials imbued with FiteBac’s broad antimicrobial...
FiteBac, manufacturer of patented antimicrobial compounds and additives for dentistryand medicine, announces partnership with RDAbbott to provide non-leaching, durableand persistent bactericidal, fungicidal, and virucidal protection in synthetic and siliconerubbers....